Condition: Rheumatic Diseases · Pediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese) · Systemic Lupus Erythematosus (SLE) · Sponsor: The Children's Hospital of Zhejiang University School of Medicine
A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA CAR-NK cell injection in patients with refractory pediatric rheumatic diseases.
This description comes directly from the study's public registry record.
Meiping Lu, Prof. · +86-13685773988 · 12218532@zju.edu.cn
Always discuss trial participation with your own doctor first.
| The Children's Hospital of Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07490041